Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...

Mounjaro. Ozempic. Wegovy. Zepbound. All these are brand names linked in some way to diabetes and weight loss-or, as the ...

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Gov. Mike Braun visited Lebanon Tuesday to help break ground for the $4.5 billion Eli Lilly Medicine Foundry in Lebanon. The foundry is the first research and development site of its kind in the world ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...